The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 20, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) partner GSK today announced that the U.S. Food and Drug Administration (FDA) has approved Hibsago ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 16, 2026-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines ...
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the company was named the top employer to work for by Science in its annual Top Employers survey of the biotech and pharmaceutical ...
Promising new Ionis-owned therapies advancing into the clinic include ION283 for Lafora disease, ION373 for a form of leukodystrophy and ION716 for prion diseases. "It's been a privilege to see Ionis' ...
"In the third quarter of 2025, we delivered strong revenue performance, highlighted by TRYNGOLZA’s nearly 70% increase over the prior quarter. As a result of this strength and our fourth quarter ...
– Study missed primary endpoint of composite outcome of cardiovascular (CV) mortality and recurrent CV events; in a pre-specified subgroup analysis, a nominally significant result was observed with ...
CARLSBAD, Calif., July 31, 2023 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the completion of enrollment in the Phase 3 CARDIO-TTRansform cardiovascular outcomes study ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Oct. 7, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today is hosting its 2025 Innovation Day in New York City. Ionis leaders will highlight the company’s ...
- Clinical outcomes: Diranersen demonstrated efficacy across all studied doses at 18 months, with consistent results across multiple prespecified clinical endpoints; the 60 mg dose showed the ...
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results